You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 62 No. 4, April 2005 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Article
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (80)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Cognitive Therapy
 •Alert me on articles by topic

Cognitive Therapy vs Medications in the Treatment of Moderate to Severe Depression

Robert J. DeRubeis, PhD; Steven D. Hollon, PhD; Jay D. Amsterdam, MD; Richard C. Shelton, MD; Paula R. Young, PhD; Ronald M. Salomon, MD; John P. O’Reardon, MD; Margaret L. Lovett, MEd; Madeline M. Gladis, PhD; Laurel L. Brown, PhD; Robert Gallop, PhD

Arch Gen Psychiatry. 2005;62:409-416.

Background  There is substantial evidence that antidepressant medications treat moderate to severe depression effectively, but there is less data on cognitive therapy’s effects in this population.

Objective  To compare the efficacy in moderate to severe depression of antidepressant medications with cognitive therapy in a placebo-controlled trial.

Design  Random assignment to one of the following: 16 weeks of medications (n = 120), 16 weeks of cognitive therapy (n = 60), or 8 weeks of pill placebo (n = 60).

Setting  Research clinics at the University of Pennsylvania, Philadelphia, and Vanderbilt University, Nashville, Tenn.

Patients  Two hundred forty outpatients, aged 18 to 70 years, with moderate to severe major depressive disorder.

Interventions  Some study subjects received paroxetine, up to 50 mg daily, augmented by lithium carbonate or desipramine hydrochloride if necessary; others received individual cognitive therapy.

Main Outcome Measure  The Hamilton Depression Rating Scale provided continuous severity scores and allowed for designations of response and remission.

Results  At 8 weeks, response rates in medications (50%) and cognitive therapy (43%) groups were both superior to the placebo (25%) group. Analyses based on continuous scores at 8 weeks indicated an advantage for each of the active treatments over placebo, each with a medium effect size. The advantage was significant for medication relative to placebo, and at the level of a nonsignificant trend for cognitive therapy relative to placebo. At 16 weeks, response rates were 58% in each of the active conditions; remission rates were 46% for medication, 40% for cognitive therapy. Follow-up tests of a site x treatment interaction indicated a significant difference only at Vanderbilt University, where medications were superior to cognitive therapy. Site differences in patient characteristics and in the relative experience levels of the cognitive therapists each appear to have contributed to this interaction.

Conclusion  Cognitive therapy can be as effective as medications for the initial treatment of moderate to severe major depression, but this degree of effectiveness may depend on a high level of therapist experience or expertise.


Author Affiliations: Departments of Psychology (Dr DeRubeis), and Psychiatry (Drs Amsterdam, Young, O’Reardon, and Gladis), University of Pennsylvania, Philadelphia; Departments of Psychology (Dr Hollon), and Psychiatry (Drs Shelton, Salomon, Lovett, and Brown), Vanderbilt University, Nashville, Tenn; Department of Mathematics and Applied Statistics, West Chester University, West Chester, Pa (Dr Gallop).


RELATED ARTICLE

Prevention of Relapse Following Cognitive Therapy vs Medications in Moderate to Severe Depression
Steven D. Hollon, Robert J. DeRubeis, Richard C. Shelton, Jay D. Amsterdam, Ronald M. Salomon, John P. O’Reardon, Margaret L. Lovett, Paula R. Young, Kirsten L. Haman, Brent B. Freeman, and Robert Gallop
Arch Gen Psychiatry. 2005;62(4):417-422.
ABSTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2000 British Association for Psychopharmacology guidelines
Anderson et al.
J Psychopharmacol 2008;22:343-396.
ABSTRACT  

Antidepressant medications v. cognitive therapy in people with depression with or without personality disorder
Fournier et al.
Br. J. Psychiatry 2008;192:124-129.
ABSTRACT | FULL TEXT  

Bibliography for Major Depressive Disorder and Suicide
Focus 2008;6:58-62.
FULL TEXT  

Abstracts For Major Depressive Disorder and Suicide
Focus 2008;6:63-68.
FULL TEXT  

Uncritical positive regard? Issues in the efficacy and safety of psychotherapy
Nutt and Sharpe
J Psychopharmacol 2008;22:3-6.
 

Cognitive Therapy Versus Medication in Augmentation and Switch Strategies as Second-Step Treatments: A STAR*D Report
Thase et al.
Focus 2008;6:104-119.
ABSTRACT | FULL TEXT  

Psychological approach to managing irritable bowel syndrome
Hayee and Forgacs
BMJ 2007;334:1105-1109.
FULL TEXT  

Utility of Observer-Rated and Self-Report Instruments for Detecting Major Depression in Women After Cardiac Surgery: A Pilot Study
Doering et al.
Am J Crit Care 2007;16:260-269.
ABSTRACT | FULL TEXT  

Cognitive Therapy Versus Medication in Augmentation and Switch Strategies as Second-Step Treatments: A STAR*D Report
Thase et al.
Am. J. Psychiatry 2007;164:739-752.
ABSTRACT | FULL TEXT  

Differences in Brain Glucose Metabolism Between Responders to CBT and Venlafaxine in a 16-Week Randomized Controlled Trial
Kennedy et al.
Am. J. Psychiatry 2007;164:778-788.
ABSTRACT | FULL TEXT  

Effects of Citalopram and Interpersonal Psychotherapy on Depression in Patients With Coronary Artery Disease: The Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) Trial
Lesperance et al.
JAMA 2007;297:367-379.
ABSTRACT | FULL TEXT  

Three decades of antidepressant, anxiolytic and hypnotic use in a national population birth cohort
Colman et al.
Br. J. Psychiatry 2006;189:156-160.
ABSTRACT | FULL TEXT  

Depression and cardiovascular disease: healing the broken-hearted.
Whooley
JAMA 2006;295:2874-2881.
ABSTRACT | FULL TEXT  

A Cognitive-Behavioral Treatment Package for Depression in Parkinson's Disease
DeFronzo Dobkin et al.
Psychosomatics 2006;47:259-263.
FULL TEXT  

Enhancing the efficacy of antidepressants with psychotherapy.
Petersen
J Psychopharmacol 2006;20:19-28.
ABSTRACT  

Neurobiological Mechanisms of the Placebo Effect
Benedetti et al.
J. Neurosci. 2005;25:10390-10402.
FULL TEXT  

Other articles noted
Evid. Based Ment. Health 2005;8:94-94.
FULL TEXT  

The Current State of Cognitive Therapy: A 40-Year Retrospective
Beck
Arch Gen Psychiatry 2005;62:953-959.
ABSTRACT | FULL TEXT  

Cognitive Therapy Versus Antidepressants for More Severe Depressions
JWatch Psychiatry 2005;2005:3-3.
FULL TEXT  

Depression Treatment: What Works? For How Long?
JWatch Women's Health 2005;2005:7-7.
FULL TEXT  

Prevention of Relapse Following Cognitive Therapy vs Medications in Moderate to Severe Depression
Hollon et al.
Arch Gen Psychiatry 2005;62:417-422.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2005 American Medical Association. All Rights Reserved.